Serial entrepreneur Eric Lefkofsky has founded or co-founded more than a dozen companies. The one that’s best known is Groupon. However, Tempus Labs, a company Lefkofsky co-founded in 2015, is now getting international interest for the role it is playing in transforming cancer research, treatment and therapies. The staff at Tempus has created technology that allows for machine reading of data from medical records as well as pathology and medical imaging, improves cancer testing, assists in the sequencing of both the RNA and DNA of tumors and makes processing organoid cultures of patient’s tumor cells easier. Tempus is revolutionizing the access to and use of big data.
The innovative new technology Tempus has devised is recognized as one of the top 10 breakthrough in modern medicine by Dr. Eric Topol. He has added it to the list of brilliant medical advances he publishes on a yearly basis. Dr. Topol’s list also includes groundbreaking scientific innovations like the KardiaBand used in artrial fibrillation diagnosis, the blood pressure watch, two new recently developed glucose sensors, artificial intelligence technology for diagnosing eye disease, the new deep-learning algorithm which diagnoses skin cancer, exciting new gene editing as well as gene therapy technology and the effective new cancer treatment called Chimeric antigen receptor T Immunotheraphy.
Born in Southfield, Michigan, Eric Lefkofsky got a bachelor’s degree from the University of Michigan in 1991 and his juris doctor from the university’s law school in 1993. He then went on to start a long list of companies. They include Brandon Apparel, print procurement company InnerWorkings, Echo Global Logistics, a freight logistics company, advertising technology company MediaBank, Mediaocean, analytics company Uptake, venture capital firm Lightbank and his most lucrative company, Groupon, one of the world’s fastest growing companies.
Eric Lefkofsky is a committed philanthropist. His Lefkofsky Family Foundation supports over 50 organizations involved in improving education, medical care, access to culture and the arts and more for children all over the world. He works with numerous Chicago, social, cultural, business and civic organizations. In 2013, Lefkofsky agreed to give his vast wealth to charity by joining The Giving Pledge.
Amicus Therapeutics has experienced tremendous growth over the past years, and recently, the company launched Galafold in Germany. The launching marked a great success of the firm which still plans to keep developing its operations and opening more branches in more countries. The firm has a high dedication towards helping people with rare conditions and has a great plan in treating the Pombe disease. As a result of the company`s commitment towards the welfare of individuals, the firm recently launched a pombe disease program, which highly targets towards offering help to all persons with the rare condition (PhillyPurge).
Many people all over the world have highly amended the services of the Amicus Therapeutics, and most people are pleased with their passion towards providing a good welfare to their clients. Besides, the excellent services that Amicus Therapeutics offer have inspired many people to treat every individual with a rare disease with caution and love. It has also been a form of encouragement to the victims with such conditions, and they barely feel rejected anymore.
Amicus Therapeutics has achieved its goal of being one of the most prestigious companies in the world that offer treatment for rare diseases and targets to keep improving as well as expanding their services in many parts of the world. The firm is currently researching a drug that will be used in the treatment of epidermolysis bullosa, a rare condition that may lead to more adverse effects if not we’ll address. The firm plans to give the results of their study starting from the third quarter. Besides, Amicus Therapeutics also aims at conducting another additional study on the treatment of the pombe disease that leads to kidney failure, heart attack, and other serious effects if not treated.
In addition to that, Amicus Therapeutics plans to establish more commercial launches in Japan and United States so as to increase the source of its capital to cater for the various treatments their offer. The excellent management of the Amicus Therapeutics has profoundly contributed to its success, and a lot is expected from the company with the starting time.